Polar Capital Holdings Plc Sells 54,339 Shares of Stoke Therapeutics, Inc. $STOK

Polar Capital Holdings Plc lessened its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 4.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,269,131 shares of the company’s stock after selling 54,339 shares during the period. Polar Capital Holdings Plc owned about 2.22% of Stoke Therapeutics worth $40,282,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics in the fourth quarter valued at approximately $26,000. Harbour Investments Inc. boosted its holdings in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after buying an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $29.15 on Wednesday. Stoke Therapeutics, Inc. has a one year low of $11.17 and a one year high of $40.22. The company has a market cap of $1.82 billion, a P/E ratio of -10.37 and a beta of 1.17. The firm’s fifty day moving average price is $32.12 and its two-hundred day moving average price is $32.36.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the transaction, the insider directly owned 34,826 shares of the company’s stock, valued at $1,064,979.08. This represents a 4.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on STOK shares. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Wedbush lifted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Finally, BTIG Research reissued a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.